Transgene appoints Simone Steiner as chief technical officer
French biotech Transgene (EPA: TNG) has named Simone Steiner as its new chief technical officer, in a move aimed at advancing the development and production of its virus-based immunotherapies.
Ms Steiner will play a central role in optimizing manufacturing for Transgene’s individualized cancer vaccines based on its myvac platform, and will also be involved in preparing a second clinical study expected to begin in the fourth quarter of 2025.
She most recently served as CTO at German biotech T-knife Therapeutics, where she led technical development and manufacturing of engineered T cell therapies. Prior to that, she was head of technical development at Swiss-based Tigen and previously spent more than a decade at Novartis (NOVN: VX) working on large-scale production strategies.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze